Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 23,750 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

NCT07324616
Conditions
Hepatic Impairment (HI)
Interventions
EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Conditions
Connective Tissue Diseases
Interventions
Belimumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania
Conditions
Metastatic Breast Cancer, Lobular Breast Carcinoma
Interventions
Blood Specimen
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
4
States / cities
San Diego, California • San Francisco, California • Philadelphia, Pennsylvania + 1 more
Conditions
Deformational Plagiocephaly, Deformational Posterior Plagiocephaly, Brachycephaly, Torticollis, Congenital Muscular Torticollis
Interventions
Repositioning Therapy, Cranial Remolding Orthosis
Other · Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Months to 3 Months
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Acne Vulgaris
Interventions
B244, Placebo
Drug
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Richardson, Texas
Conditions
Systemic Lupus Erythematosus
Interventions
Budoprutug
Drug
Lead sponsor
Climb Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Allen, Texas • San Antonio, Texas
Conditions
Psoriasis
Interventions
BMS-986165, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
101
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 77 more
Conditions
Dermatitis, Atopic
Interventions
Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
3,166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
156
States / cities
Birmingham, Alabama • Anaheim, California • Encinitas, California + 101 more
Conditions
Triple Negative Breast Cancer
Interventions
adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment
Biological · Device · Other
Lead sponsor
OBI Pharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
12
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 9 more
Completed Phase 1 Interventional Accepts healthy volunteers

Silk Scaffold Surgical Incision Dressing

NCT05508945
Conditions
Surgical Incision
Interventions
Dermabond Prineo Skin Closure System, silk, 3M Steri-Strip
Device
Lead sponsor
Mehrdad Mark Mofid
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
La Jolla, California
Conditions
Mesothelioma
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
6
States / cities
Baltimore, Maryland • Rochester, Minnesota • New York, New York + 2 more
Conditions
Recurrent Osteosarcoma, Refractory Osteosarcoma
Interventions
Docetaxel, Gemcitabine, Hydroxychloroquine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Recruiting Phase 1 Interventional Accepts healthy volunteers

1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)

NCT07155239
Conditions
Hidradenitis Suppurativa (HS)
Interventions
AviClear Lase Treatment, Sham (No Treatment)
Device
Lead sponsor
Wynn Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rosemead, California
Conditions
Leukemia, Lymphoma
Interventions
rituximab, fludarabine phosphate, pixantrone dimaleate
Biological · Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Breast Carcinoma
Interventions
Biospecimen Collection, Low-Dose Aspirin, Questionnaire Administration, Biopsy
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 2 more
Conditions
Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder, Bone Marrow Failure, Dyskeratosis Congenita, Telomere Biology Disorders
Interventions
Total Body Irradiation (TBI) (Plan 1), Cyclophosphamide (CY) (Plan 1), Fludarabine (FLU), Methylprednisolone (MP), Donor mobilized PBSC infusion, G-CSF, Cyclophosphamide (CY) (Plan 2), Rituximab, Busulfan, Alemtuzumab, Melphalan
Drug · Device
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Breast Cancer
Interventions
SPY Intra-Operative Angiography
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Stanford, California
Conditions
Breast Cancer
Interventions
Biomarkers
Other
Lead sponsor
Sentara Norfolk General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Newport News, Virginia • Norfolk, Virginia
Conditions
Premature Newborn, Necrotizing Enterocolitis
Interventions
Citrulline samples
Diagnostic Test
Lead sponsor
University of Miami
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Miami, Florida
Conditions
Cellular Injury and Post-Cryogenic Recovery, Cryogenic Cellular Stress, Cold-Induced Cellular Injury, Thermal Injury Response, Post-Thaw Viability Impairment, Osmotic Stress Injury, Biomechanical Injury Modeling (In-Vitro), Blunt Force Injuries to the Extremities (Cellular Injury Model), Tissue Damage and Recovery Pathways, Hypothermic Tissue Stress, Cellular Regeneration and Repair
Interventions
Standard Laboratory Cryopreservation Procedure, Enhanced Laboratory Cryopreservation Procedure, Normothermic Cell Culture Control
Other
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2066
U.S. locations
1
States / cities
New York, New York
Conditions
Tenosynovial Giant Cell Tumor
Interventions
Not listed
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Wilmington, North Carolina
Conditions
Male Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
oblimersen sodium, doxorubicin hydrochloride, docetaxel, filgrastim, pegfilgrastim, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
Biological · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Systemic Scleroderma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Intensity-Modulated Radiation Therapy, Total-Body Irradiation
Procedure · Drug · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Terminated Phase 1 Interventional Results available

Ipilimumab and Local Radiation for Selected Solid Tumors

NCT01769222
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Colon Cancer, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Melanoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Rectal Cancer, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
Ipilimumab, Radiation therapy
Biological · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Stanford, California